Xin Lang Cai Jing·2025-09-15 02:35Core Viewpoint - BeiGene's stock has shown significant growth this year, with a year-to-date increase of 99.95%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - As of September 15, BeiGene's stock price reached 321.96 CNY per share, with a trading volume of 8.29 billion CNY and a turnover rate of 2.27%, resulting in a total market capitalization of 496.04 billion CNY [1]. - The stock has experienced a 1.25% increase over the last five trading days, a 32.49% increase over the last 20 days, and a 28.58% increase over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a stock trading list) once this year, with the most recent appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, BeiGene reported a revenue of 17.518 billion CNY, representing a year-on-year growth of 46.03%, and a net profit attributable to shareholders of 450 million CNY, which is a 115.63% increase compared to the previous period [2]. - The number of shareholders decreased by 3.90% to 23,300 as of June 30, 2025, while the average number of circulating shares per person increased by 4.11% to 4,976 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, the fourth largest shareholder is 中欧医疗健康混合A (China Europe Medical Health Mixed A) with 4.8254 million shares, an increase of 1.2436 million shares from the previous period [2]. - 万家优选 (Wanjia Youxuan) is the sixth largest shareholder with 3 million shares, a decrease of 500,000 shares [2]. - 新进股东 (new shareholder) 南方中证500ETF (Southern CSI 500 ETF) holds 1.7259 million shares [2].